Clinical Trial Update: A Study of Patients With Pure Red Cell Aplasia Associated With Recombinant Human Erythropoietin Treatment

View source ↗

Summary

A completed clinical trial investigating pure red cell aplasia associated with recombinant human erythropoietin treatment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pure Red Cell Aplasia

Drugs mentioned

• Recombinant human erythropoietin (erythropoietin)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Pure Red-cell Aplasia | Status: COMPLETED